AbbVie (ABBV) Invested Capital (2012 - 2026)

AbbVie (ABBV) has 15 years of Invested Capital data on file, last reported at -$6.7 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at -$6.7 billion, down 227.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.7 billion (down 227.24% YoY), and the FY2025 annual result was $61.7 billion, down 12.45% from the prior year.
• Invested Capital retreated to -$6.7 billion in Q1 2026 per ABBV's latest filing, from $61.7 billion in the prior quarter.
• Over five years, Invested Capital peaked at $80.6 billion in Q4 2022 and troughed at -$6.7 billion in Q1 2026.
• A 5-year average of $24.9 billion and a median of $16.1 billion in 2023 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2026: Invested Capital surged 50.47% in 2024, then tumbled 227.24% in 2026.
• A 5-year view of Invested Capital shows it stood at $80.6 billion in 2022, then retreated by 13.38% to $69.8 billion in 2023, then rose by 1.04% to $70.5 billion in 2024, then slipped by 12.45% to $61.7 billion in 2025, then slumped by 110.78% to -$6.7 billion in 2026.
• Business Quant data shows ABBV's Invested Capital at -$6.7 billion in Q1 2026, $61.7 billion in Q4 2025, and -$660.0 million in Q3 2025.